Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
about
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumoursChemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer.Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potentialIncidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.Increased efficacy of breast cancer chemotherapy in thrombocytopenic miceSaddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma.Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.Semaphorin 7A inhibits platelet production from CD34+ progenitor cells.Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamideAdvances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Designer cytokine hyper interleukin 11 (H11) is a megakaryopoietic factorSequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP).Angiotensin 1 - 7 stimulation of platelet recovery.Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways.Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in KoreaComplex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.Growth factor use in medication-induced hematologic toxicity.Feasibility of an Isometric Maximal Voluntary Contraction Test in Hematological Cancer Patients during Thrombocytopenia.Effects of Designer Hyper-Interleukin 11 (H11) on Hematopoiesis in Myelosuppressed MiceCarboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions.Role of factor xa inhibitors in cancer-associated thrombosis: any new data?Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients.A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancerMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.Platelet factor 4 platelet levels are inversely correlated with steady-state platelet counts and with platelet transfusion needs in pediatric leukemia patients.Senior adult oncology.Surgical management of rhinosinusitis in onco-hematological patientsIL-11 signaling as a therapeutic target for cancer.SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC.Gamma-Glutamylcysteine Ethyl Ester Protects against Cyclophosphamide-Induced Liver Injury and Hematologic Alterations via Upregulation of PPARγ and Attenuation of Oxidative Stress, Inflammation, and Apoptosis.Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.D-dencichine Regulates Thrombopoiesis by Promoting Megakaryocyte Adhesion, Migration and Proplatelet Formation.Study of Imidazolium Salt Derivatives as PIK3CA Inhibitors Using a Comprehensive in Silico Method.
P2860
Q24186714-DAE10336-3E61-4CFF-B21D-0EC69A7E6C1BQ33389009-B0DAF88A-BEC4-443F-B9DB-7A382103EEF2Q33389662-7147D395-BEDB-4985-B33E-73F0CAAEE3A4Q33391777-037C6264-8CEC-41BE-AA6D-68DF77CC590BQ33393552-07DCB470-58BA-4612-A9AF-5E2E96EC6589Q33393653-564E78DE-E15C-48B4-96BA-1E8C51CA9631Q33397149-4B0A4E09-6E16-4422-BF18-A88125A3F352Q33400401-5101A4B5-2A70-47D5-BC5B-64837A741D15Q33406493-A20E69D4-FA3C-475A-99D6-8B2B635C2E80Q33407110-5A81238C-2187-427B-A877-9606C309819BQ33409225-94C7211B-E6B9-4C16-A72B-BD3FA1966B81Q33409463-C85B5E90-BD8D-43D7-930B-F4FAD8981279Q33412108-C1102FBA-C19B-49C5-BB64-4C0AE5EC9503Q33413442-27C70AEC-2C52-4E16-AB49-B77549705681Q33413970-791DEBAE-C1EF-4F60-BDE5-724F4D90ADF7Q33416602-1BB4FE62-DEF2-4922-96A3-ACE55A86FBCAQ33417707-DC78D891-8FE0-4DA8-8A68-9CE8852C8464Q33417812-A931A8FC-42C1-4F11-9AAD-94E862C0CD41Q33426701-6D7A4358-CB60-4E47-BEB9-F440A840613BQ33431967-2693BE5D-2936-4B4F-9D1E-54C9309CD42EQ33436456-1DCC1331-ECE9-479F-8810-6E727B2A2CBFQ34052232-DDBCE861-1CFB-42DC-9ECA-7E7E27A349FAQ35042007-7E9B224D-88CA-48B4-9BC8-E97DFA5B4804Q35584817-A05E2966-CB58-452C-858A-3635310B3FBBQ35842970-95D69BDC-66B6-4E62-996C-CCC81289ABBDQ36075713-DBE7A3E5-268D-4702-85DC-E8D09BBF3604Q36851424-3FC55251-79BD-4FA3-BBA9-8C61CD4CEA96Q38272990-0504AE31-AA6E-4E92-9507-42EAD004E613Q38445355-E353708A-9A48-43E9-AA06-149ABC96427FQ39000853-427F869B-4189-4006-8C1D-E49D7612BD59Q39028144-366BFB1D-1788-4D73-A58C-1C504FD0C8A5Q47409875-2EB1C863-171D-4370-80BA-8D99B1DB3FE3Q52581888-6ACB9ED7-C384-4B0D-9BB6-A3DAD89D8C4DQ52644535-B44EAA8B-653B-45DB-85DB-2BCC2F82A877
P2860
Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@ast
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@en
type
label
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@ast
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@en
prefLabel
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@ast
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@en
P1476
Management of chemotherapy-ind ...... atus of thrombopoietic agents.
@en
P2093
Saroj Vadhan-Raj
P304
P356
10.1053/J.SEMINHEMATOL.2008.12.007
P433
P577
2009-01-01T00:00:00Z